Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic

29Citations
Citations of this article
59Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE, are an increasing problem world-wide, causing intractable wound infections. Complex phytochemical extracts such as tea tree oil and eucalypt-derived formulations have been shown to have strong bactericidal activity against MRSA in vitro. Polytoxinol (PT) antimicrobial, is the trade name of a range of antimicrobial preparations in solution, ointment and cream form. Methods: We report the first use of this drug, administered percutaneously, via calcium sulphate pellets (Osteoset,TM), into bone, to treat an intractable MRSA infection of the lower tibia in an adult male. Results and Discussion: Over a three month period his symptoms resolved with a healing response on x-ray and with a reduced CRP.

Cite

CITATION STYLE

APA

Sherry, E., Boeck, H., & Warnke, P. H. (2001). Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic. BMC Surgery, 1, 1–3. https://doi.org/10.1186/1471-2482-1-1

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free